Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Project: Research

Project Details

Effective start/end date13/08/2012/08/25


  • clinical trial
  • phase 1 study
  • treatment safety
  • treatment efficacy
  • solid tumours